Skip to main content

Additional Articles by the Authors

Jeffrey T. Guptill, MD, MA, MHS
Michael C. Runken, PharmD
Michael Eaddy, PharmD, PhD
Orsolya Lunacsek, PhD
Rupali M. Fuldeore, MS
Michael C. Runken, PharmD; Joshua M. Noone, PhD; Christopher M. Blanchette, PhD, MBA; Emily Zacherle, MS; Reuben Howden, PhD
Shared Decision-Making and Payer Preferences: IVIG or SCIG Route of Administration?
Gary M. Owens, MD
Jordan S. Orange, MD, PhD; Matt Johnson, BA; Barb Lennert, RN, BSN, MAOM; Katarzyna Shields, PharmD, MBA, BCOP, BCPS; Michael Eaddy, PharmD, PhD
A Useful Tool for Evaluating Disease Severity and Alternative Treatments Efficacy
Gary Branning, MBA
Todd Williamson, MsC; Rajesh Kamalakar, MS; Augustina Ogbonnaya, MPH; Erin A. Zagadailov, PharmD, MS; Michael Eaddy, PharmD, PhD; Charlie Kreilick, MBA
The Challenge of Rosacea Treatment
Atheer A. Kaddis, PharmD
Important Insights from Real-World Treatment Patterns and Outcomes for Varicose Veins Management
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
A Teachable Moment in Health Benefits Design
Out-of-Pocket Cost of Therapy Can Affect Patients’ Excessive Sleepiness and Daytime Functioning
We Need More Research on True Value-Based Benefit Design that Will Improve Outcomes and Control Costs
Benefit Management Considerations for BPH Medications: Single Agent or Combination Therapy?

Results 1 - 9 of 9